Condiciones de salud que ácido rosmarínico puede ayudar a apoyar.
Rosmarinic acid, a polyphenolic phytochemical enriched in Perilla frutescens, was directly tested in a 21-day randomized double-blind placebo-controlled trial in seasonal allergic rhinoconjunctivitis patients and significantly reduced neutrophils and eosinophils in nasal lavage fluid versus placebo. It suppresses passive cutaneous anaphylaxis and reduces allergen-specific IgE responses in murine models. Rosmarinic acid inhibits IgE-mediated mast cell degranulation and complement activation.
Rosmarinic acid (RA) is a polyphenolic compound with well-documented antioxidant properties demonstrated across in vitro and in vivo experimental models. Its primary mechanism involves activation of the Nrf2 signaling pathway, which upregulates endogenous antioxidant enzymes including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and heme oxygenase-1 (HO-1). The evidence base is predominantly preclinical; dedicated human RCTs measuring antioxidant defense biomarkers as primary endpoints remain limited, and RA's oral bioavailability is constrained by extensive phase-II conjugation at physiological pH.
Rosmarinic acid (RA), primarily through RA-rich lemon balm (Melissa officinalis) extracts, has shown anxiolytic effects in multiple human clinical trials. A 2022 randomized, double-blind, placebo-controlled trial found rosemary capsules (containing quantified RA) significantly reduced Hospital Anxiety and Depression Scale anxiety subscale scores in patients with major depressive disorder over 8 weeks. Preclinical work indicates RA modulates the HPA axis and BDNF signaling to reduce anxiety-like behavior.
Rosmarinic acid (from rosemary, sage, lemon balm, and mint) inhibits ACE, reduces NF-κB-driven vascular inflammation, inhibits LDL oxidation, and has documented antioxidant effects in arterial tissue. It was identified as one of 12 Danshen/rosemary bioactives that synergistically reduced arterial stiffness in a human RCT of smokers.
Rosmarinic acid has well-documented anti-arthritic activity in preclinical models of both osteoarthritis and rheumatoid arthritis, reducing cartilage degradation, synovial inflammation, and joint inflammatory markers. In vitro studies using T cells from rheumatoid arthritis patients showed RA induced apoptosis of activated T cells via the mitochondrial pathway.
Rosmarinic acid has demonstrated anti-asthmatic activity in multiple preclinical models, reducing airway eosinophilia, IgE, Th2 cytokines, and airway hyperresponsiveness. One human clinical trial on seasonal allergic rhinoconjunctivitis provides direct human anti-inflammatory airway evidence. Preclinical mechanistic evidence shows RA acts via gut-lung axis microbiota modulation alongside direct lung anti-inflammatory pathways.
Rosmarinic acid modulates autoreactive T-cell activity by inducing apoptosis of activated T cells (demonstrated directly in cells from rheumatoid arthritis patients), inhibiting complement activation, and suppressing pro-inflammatory cytokine production from immune cells. These actions are mechanistically relevant across autoimmune diseases including RA, lupus-related glomerulonephritis, and atopic conditions.
Rosmarinic acid has demonstrated antihypertensive effects in multiple preclinical models via ACE inhibitory and vasodilatory mechanisms. In angiotensin-II-treated hypertensive rats, both acute and chronic RA lowered blood pressure dose-dependently. In fructose-fed rats, RA (10 mg/kg for 45 days) improved blood pressure alongside metabolic markers.
Rosmarinic acid has demonstrated hypoglycemic and glucose-regulatory effects in multiple preclinical models including STZ-induced type 1 diabetic rats and high-fat-diet-induced type 2 diabetic rats. Mechanisms include upregulation of GLUT4 expression in muscle and downregulation of hepatic PEPCK, reducing gluconeogenesis. Human clinical data are limited, but RA's effects on glucose homeostasis are robustly documented at the preclinical level.
Human double-blind, placebo-controlled, crossover trials using RA-standardized lemon balm drinks have demonstrated improvements in contentment, reduced anger, and a calming effect on mood in healthy adults. These effects were observed acutely, correlating with measurable plasma absorption of rosmarinic acid. The calming effects appear mediated partly through GABAergic and BDNF-related pathways.
Rosmarinic acid demonstrated significant total cholesterol and LDL-related lipid-lowering effects in high-fat-diet-fed mouse models, mediated by upregulation of hepatic SR-B1 and LDL receptor expression via the reverse cholesterol transport pathway. In vitro, RA also countered oleic-acid-induced cholesterol accumulation in hepatocytes.
Rosmarinic acid exerts well-characterized anti-inflammatory actions via inhibition of NF-κB, COX-2, and 5-LOX pathways, reduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and complement inhibition. These mechanisms have been confirmed in vitro and in multiple in vivo animal models. A human clinical trial confirmed RA reduces neutrophil and eosinophil infiltration in allergic (inflammatory) conditions, providing direct human anti-inflammatory evidence.
RA-standardized Melissa officinalis extracts have shown cognitive-stabilizing effects in patients with mild-to-moderate Alzheimer's disease in multiple RCTs. RA inhibits amyloid-beta fibril formation, protects against neuroinflammation, and supports BDNF-dependent neuroplasticity. A 2025 narrative review concluded lemon balm (RA-standardized) can stabilize cognitive function in mild cognitive impairment and early AD.
Rosmarinic acid exhibits antidepressant-like effects in preclinical models via modulation of BDNF/TrkB/PI3K signaling, glucocorticoid receptor nuclear translocation, and hippocampal neurogenesis. A 2022 human RCT found rosemary (containing quantified RA) significantly reduced BDI depression scores as adjunctive therapy to SSRIs over 8 weeks. A 2021 meta-analysis confirmed RA-rich lemon balm extract improves depression scores across multiple clinical trials.
A human clinical study demonstrated that topical 0.3% rosmarinic acid emulsion significantly reduced erythema, SCORAD, pruritus, and transepidermal water loss in atopic dermatitis patients over 8 weeks. In vitro and animal models further confirm RA suppresses IgE-mediated and T-cell-driven dermatitis pathways. RA also activates NHE1 to lower skin pH, improving barrier function in inflammatory skin conditions.
A published human clinical study demonstrated that topical 0.3% rosmarinic acid emulsion applied twice daily for 8 weeks to atopic dermatitis (eczema) patients significantly reduced erythema, SCORAD index, pruritus, and transepidermal water loss. No adverse reactions were observed in patch testing. These findings support RA as a potential topical therapeutic for mild atopic eczema.
Rosmarinic acid has demonstrated anticonvulsant properties in preclinical seizure models, attributed primarily to GABA transaminase inhibition (raising brain GABA levels) and inhibition of excitatory neurotransmitter pathways. These are well-characterized preclinical mechanisms; no human RCTs for epilepsy with RA have been conducted.
Double-blind, placebo-controlled crossover human trials with RA-standardized lemon balm preparations demonstrated improvements in alertness, word recognition, and working memory in healthy adults. These cognitive effects were correlated with measured plasma rosmarinic acid levels peaking approximately one hour post-consumption.
Rosmarinic acid has demonstrated anti-inflammatory and gastroprotective effects in preclinical gastric mucosal injury models, reducing mucosal inflammation via NF-κB suppression and antioxidant activity. Traditional use of RA-containing Lamiaceae plants (rosemary, lemon balm) for gastric complaints provides complementary traditional context. Dedicated human gastritis RCTs with RA are absent.
Preclinical studies demonstrate that rosmarinic acid modulates gut microbiota composition, increasing short-chain fatty acid (SCFA)-producing bacteria while reducing LPS-producing pathobionts. In allergic asthma models, RA's anti-asthmatic effects were partially mediated through the gut-lung axis via microbiome modulation. RA's low oral bioavailability means it interacts substantially with colonic microbiota.
Rosmarinic acid is the primary hydroxycinnamic acid in rosemary, lemon balm, perilla, and sage with potent antioxidant and anti-inflammatory activity. Multiple human studies demonstrate its ability to reduce allergic inflammation, oxidative stress markers, and neuroinflammation — all components of inflammaging. It inhibits NF-κB and activates Nrf2.
Rosmarinic acid has demonstrated cardioprotective properties in preclinical models, including angiotensin-converting enzyme (ACE) inhibition, vasodilation, reduction of oxidative-stress-related cardiac damage markers, and improvement of cardiac lipid profiles in fructose-fed hypertensive rats. RA also exhibits lipid-lowering effects via reverse cholesterol transport modulation.
Rosmarinic acid has demonstrated anti-colitis activity in multiple preclinical IBD models (DSS-induced and TNBS-induced colitis), reducing colon inflammation, mucosal damage, and inflammatory cytokine levels via NF-κB and MAPK pathway suppression. The 2020 Frontiers in Pharmacology review explicitly identifies colitis as a primary disease target for RA's anti-inflammatory effects.
Multiple preclinical studies demonstrate rosmarinic acid improves insulin sensitivity in high-fat-diet and fructose-fed animal models, increasing GLUT4 expression in skeletal muscle, decreasing PEPCK expression in liver, and reducing HOMA-IR. These effects are dose-dependent and have been demonstrated in both type 1 and type 2 diabetic animal models.
Rosmarinic acid has shown renoprotective effects in preclinical models, protecting against oxidative damage, reducing inflammation in renal tissue, and being investigated in combined hypertension-diabetes-nephrolithiasis rat models. In hemodialysis contexts, RA-supplemented dialysate reduced pro-inflammatory cytokine production from human vascular endothelial cells. However, direct human RCTs for kidney outcomes are absent.
Rosmarinic acid has well-documented hepatoprotective effects in preclinical models, reducing liver damage from chemical toxins (CCl4, LPS/D-galactosamine), cholestasis, and NAFLD via Nrf2 pathway activation, NF-κB suppression, and antioxidant enzyme induction. A comprehensive review (PMID 30780110) characterizes RA's hepatoprotective mechanisms as among its most robustly documented pharmacological properties.
Rosmarinic acid demonstrates lung-protective activity in preclinical models of acute lung injury, reducing NF-κB-driven pulmonary inflammation and oxidative stress. In a thermal injury systemic inflammation model, RA reduced multi-organ dysfunction markers including lung injury biomarkers. Preclinical evidence for asthma is supported by one human clinical trial for allergic airway disease.
RA-standardized Melissa officinalis extracts have improved memory measures in human clinical trials, including word recognition in healthy adults and cognitive stabilization in mild-to-moderate Alzheimer's disease. Preclinical models show RA reduces amyloid-beta aggregation and prevents Aβ-induced memory impairment. Evidence is based primarily on RA-containing plant preparations rather than isolated RA.
Rosmarinic acid targets multiple components of metabolic syndrome simultaneously in preclinical models: reducing blood pressure (via ACE inhibition), lowering blood glucose and improving insulin sensitivity, reducing plasma triglycerides and cholesterol, and decreasing systemic inflammatory tone. This multi-target activity makes RA a candidate for metabolic syndrome management.
Rosmarinic acid protects mitochondrial function in neuronal cells by restoring mitochondrial membrane potential, preserving ATP content, inhibiting ROS overproduction, and attenuating mitochondrial unfolded protein response (mtUPR). These effects are documented in MPTP Parkinson's disease models and oxaliplatin-induced peripheral neuropathy models.
Rosmarinic acid mitigates peripheral neuropathy in preclinical models, including oxaliplatin-induced peripheral neuropathy where it reduced mitochondrial dysfunction and spinal glial activation. RA's neuroprotective mechanisms include antioxidant activity, anti-neuroinflammatory effects, and protection of neuronal mitochondrial function. Human-specific clinical evidence for neuropathy is not yet available.
Rosmarinic acid has demonstrated neuroprotective effects in multiple preclinical Parkinson's disease models (MPTP, rotenone, 6-OHDA), protecting dopaminergic neurons via antioxidant, anti-neuroinflammatory, and mitochondrial-protective mechanisms. RA reduces α-synuclein accumulation and HMGB1/TLR4/NF-κB neuroinflammatory signaling in PD models. No human clinical trials for RA in PD have been published.
Rosmarinic acid induced apoptosis of activated T cells isolated from rheumatoid arthritis patients via the mitochondrial pathway — providing direct human-cell-level evidence of immune modulation in RA. Preclinical animal models confirm RA reduces joint inflammation, cartilage damage, and synovial cytokine production. RA's T-cell apoptosis mechanism is analogous to, but potentially safer than, immunosuppressive drugs used for RA.
A 21-day randomized double-blind placebo-controlled trial (Takano et al., Exp Biol Med, 2004; Osakabe et al., Biofactors, 2005) found rosmarinic acid significantly improved itchy nose, watery eyes, itchy eyes, and total symptom response rates in seasonal allergic rhinoconjunctivitis, and reduced nasal neutrophil and eosinophil counts. It inhibits PMNL infiltration via NF-κB suppression and ROS scavenging.
Rosmarinic acid, concentrated in Perilla frutescens and also found in rosemary and other herbs, was tested in a 21-day randomized, double-blind, placebo-controlled trial in seasonal allergic rhinoconjunctivitis patients. Active treatment significantly increased responder rates for itchy nose, watery eyes, itchy eyes, and total symptoms, and significantly reduced neutrophils and eosinophils in nasal lavage fluid.
Rosmarinic acid exhibits multiple anti-aging properties relevant to skin: potent antioxidant activity (neutralizing UV-induced ROS), inhibition of matrix metalloproteinases (which degrade collagen), anti-inflammatory effects reducing chronic low-grade skin inflammation, and improvement of skin barrier function via NHE1 activation. These effects are documented primarily in preclinical and in vitro studies.
RA-standardized Melissa officinalis (lemon balm) extracts have improved sleep quality in clinical populations including postmenopausal women (combined with valerian) and cardiac patients. RA's sleep-promoting mechanism involves GABA transaminase inhibition, prolonging GABAergic calming neurotransmission. A 2017 RCT with rosemary (containing RA) also reported sleep quality improvements in university students.
Human clinical evidence supports RA-rich lemon balm extracts reducing subjective and physiological stress responses. Double-blind, crossover trials in healthy adults showed reduced negative mood under lab-induced stress (multitasking framework), reduced anger, and improved stress-resilience measures. RA attenuates HPA-axis activation and BDNF dysregulation induced by repetitive stress in animal models.
Rosmarinic acid (RA), a natural phenolic compound found in rosemary and related herbs, has demonstrated photoprotective potential when incorporated into sunscreen formulations. A 2025 PMC study showed RA enhanced both in vitro and in vivo photoprotection of UVB filters and reduced oxidative stress in the stratum corneum. It is classified as a potential non-filtering photoprotective additive.
Rosmarinic acid has demonstrated triglyceride-lowering effects in preclinical lipid models. In high-fat-diet-fed mice, RA treatment significantly decreased plasma triglyceride levels alongside total cholesterol reduction, via modulation of reverse cholesterol transport and lipid metabolism genes in liver. In HepG2 hepatocyte models, RA also countered oleic acid-induced triglyceride accumulation.
A published human clinical trial demonstrated that oral rosmarinic acid (50 mg or 200 mg/day for 21 days) significantly reduced symptoms of seasonal allergic rhinoconjunctivitis (SAR), decreased nasal neutrophil and eosinophil counts, and outperformed placebo. RA has also been documented in traditional use for upper respiratory complaints in Lamiaceae herbal medicine.
Rosmarinic acid has demonstrated antiviral activity in vitro against multiple viruses including herpes simplex virus (HSV-1, HSV-2), influenza, enterovirus, and SARS-CoV-2 pseudovirus. Mechanisms include inhibition of viral attachment, replication, and viral protease activity. No human RCTs specifically for RA as an antiviral agent have been conducted.
Rosmarinic acid, found in rosemary, sage, comfrey, and basil, has documented anti-inflammatory and antioxidant wound-healing properties. It inhibits 5-lipoxygenase and COX-2, reduces oxidative stress at wound sites, and has been identified as a key active compound in comfrey-based wound preparations.
Volver